|
|
|
|
|
In 1988 Dr. Camillo Ricordi revolutionized a method of transplantation of islet cells (cells that produce insulin) which remains the gold standard for human pancreas processing today. The problem is, like with so many other types of transplantation, the body often rejects the new cells. All that could change with the introduction of this anti-rejection antibody – Novus Therapeutics, Inc. (NASDAQ:NVUS) – CD40/CD40L – FDA Phase II. Join Dr. Ricordi and his world-class panel of experts who weigh-in on the likelihood of this medical breakthrough. They also look at what the future may hold for investors in the technology, and those who are considering an investment. It’s T1D-Day, with the hopeful surrender of this debilitating disease just around the corner. Panelists: Dr. Camillo Ricordi, Director of the Diabetes Research Institute at the University of Miami School of Medicine – Ranked as the World Leader in Islet Cell Transplant Dr. James Markmann, Chief of the Division of Transplant Surgery and Director of Clinical Operations at the Transplant Center at Massachusetts General Hospital, and the Claude Welch Professor of Surgery at Harvard Medical School Dr. Norma Sue Kenyon, Martin Kleiman Professor of Surgery, Microbiology and Immunology and Biomedical Engineering, Vice Provost for Innovation Dr. David Gros, Chief Executive Officer Novus Therapeutics Dr. Steven Perrin, President & CSO, Novus Therapeutics. |